Checkpoint Kinase Inhibitor Pipeline Analysis: Key Pharma Companies, and Emerging Therapies Offering New Horizons in Cancer Care
Several pharmaceutical companies are developing the Checkpoint Kinase Inhibitors as one of the most promising therapies owing to the treatment of Cancer and Advanced solid tumors.
DelveInsight’s ‘Checkpoint Kinase Inhibitor Pipeline Insights’ report lays out a complete view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the Checkpoint Kinase Inhibitor landscape.
Some of the key highlights of the Checkpoint Kinase Inhibitor Pipeline report:
- Checkpoint Kinase Inhibitor Pipeline report offers a detailed analysis of 10+ key players and 10+ key pipeline therapies.
- Checkpoint Kinase Inhibitor pipeline comprises SRA737 (Sierra Oncology), PHI 101 (Pharos I&BT), BI 765063 (Boehringer Ingelheim), V158411 (Vernalis), SOL-578 (Sentinel Oncology), and several others in different stages of clinical trials.
- SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1) being developed by Sierra Oncology. The drug has recently completed two Phase I/II clinical trials for the treatment of Advanced Solid tumors.
- Drug discovery activities at Vernalis and with collaborators have generated V158411 and VER250840, Checkpoint Kinase 1 inhibitors as pre-clinical candidates.
Checkpoint Kinases
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The development of Checkpoint Kinase Inhibitors to treat cancer has been a major objective in drug discovery. Checkpoint Kinases are protein kinases, Chk1 and Chk2, Ser/Thr protein kinases, which function as key regulatory kinases in cellular DNA damage response pathways limiting cell-cycle progression in the presence of DNA damage.
Checkpoint kinase 1 (CHK1) is an oncology target of significant current interest. Inhibition of CHK1 abrogates DNA damage-induced cell cycle checkpoints and sensitizes p53 deficient cancer cells to genotoxic therapies.
Source: Globenewswire